STRIDE-PsA
Research type
Research Study
Full title
STRIDE-PsA: A Study of Treatment Response and Immunogenicity in Sequential Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug (b/tsDMARD) Exposure in Psoriatic Arthritis
IRAS ID
362489
Contact name
James Kimpton
Contact email
Sponsor organisation
Royal United Hospitals Bath NHS Foundation Trust
Duration of Study in the UK
3 years, 0 months, 4 days
Research summary
Psoriatic arthritis (PsA) is a lifelong inflammatory condition characterised by joint pain, swelling and stiffness, affecting around 190,000 people in the UK. It can greatly impact daily life, reduce work productivity, and lower overall quality of life.
Up to half of people with PsA require treatment with advanced, high-cost medicines called biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). However, approximately 40% of patients on b/tsDMARDs stop or switch treatments due to side effects, inefficacy or co-morbidities after one year, and the majority switch by three years.
There is little evidence on how well people respond after several treatment switches, especially beyond the third advanced therapy. This lack of information has contributed to regional differences in access to treatment, with around one in four rheumatologists facing limits on the number of advanced therapies they can prescribe. We also know little about people’s experiences of switching or the reasons why clinicians recommend a change.
One possible reason for treatment failure is the development of “anti-drug antibodies” (ADAs). These are proteins made by the immune system that can attach to the drug, reducing its level in the blood or blocking its effect. Some people may even have ADAs before starting treatment, but their role in PsA is not yet understood.
This study, called STRIDE-PsA, will follow people with PsA who are starting a new b/tsDMARD. We will assess symptoms and quality of life, and take a small blood sample before treatment and again at 12 weeks to measure drug levels and different types of ADAs. By comparing results between earlier and later lines of treatment, we aim to find out whether responses diminish with repeated switches and whether ADAs can help predict treatment success. The results could help guide more personalised, effective care for people living with PsA.
REC name
London - Bloomsbury Research Ethics Committee
REC reference
26/PR/0053
Date of REC Opinion
11 Feb 2026
REC opinion
Further Information Favourable Opinion